Gossamer Bio Revenue and Competitors
Estimated Revenue & Valuation
- Gossamer Bio's estimated annual revenue is currently $6M per year.
- Gossamer Bio received $230.0M in venture funding in July 2018.
- Gossamer Bio's estimated revenue per employee is $33,033
- Gossamer Bio's total funding is $480M.
- Gossamer Bio's current valuation is $906.1M. (January 2022)
Employee Data
- Gossamer Bio has 183 Employees.
- Gossamer Bio grew their employee count by -22% last year.
Gossamer Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, CEO and Chairman | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Chief Commercial Officer | Reveal Email/Phone |
4 | Executive Director Business Development | Reveal Email/Phone |
5 | VP | Reveal Email/Phone |
6 | SVP, Biometrics | Reveal Email/Phone |
7 | VP Clinical Operations | Reveal Email/Phone |
8 | VP, Pulmonary Vascular Disease | Reveal Email/Phone |
9 | VP, Clinical Pharmacology & Development | Reveal Email/Phone |
10 | General Counsel | Reveal Email/Phone |
Gossamer Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Gossamer Bio?
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio's strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
keywords:N/A
$480M
Total Funding
183
Number of Employees
$6M
Revenue (est)
-22%
Employee Growth %
$906.1M
Valuation
N/A
Accelerator
Gossamer Bio News
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Rating of Buy from Analysts. Posted by admin on Apr 17th, 2022.
Other analysts have also issued reports about the company. Sumitomo Mitsui Financial Group upgraded Gossamer Bio from a neutral rating to an ...
Gossamer Bio [[GOSS, +8%]] was initiated with a Buy at UBS with a price target of $19. UBS said it thinks Gossamer's (NASDAQ:GOSS) clinical...
SAN DIEGO--(BUSINESS WIRE)--Feb 25, 2021-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial re ...
Artal Group S.A. trimmed its position in Gossamer Bio Inc (NASDAQ:GOSS) by 3.0% in the 2nd quarter, according to the company in its most ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $33.2M | 183 | -8% | N/A |
#2 | $46M | 183 | 24% | $206.1M |
#3 | $32.4M | 184 | 10% | N/A |
#4 | $30.5M | 185 | 10% | N/A |
#5 | $54.9M | 185 | 24% | N/A |
Gossamer Bio Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-01-08 | $100.0M | Undisclosed | Omega Funds | Article |
| 2018-07-24 | $230.0M | Hillhouse Capital | Article |